{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T11:56:38Z","timestamp":1769255798130,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-024-03840-y","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T14:18:55Z","timestamp":1737469135000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["\u201cIf that would have lessened my symptoms, that would have been great...\u201d: a qualitative study about the acceptability of tecovirimat as treatment for mpox"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1909-2481","authenticated-orcid":false,"given":"Sara","family":"Paparini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4046-4101","authenticated-orcid":false,"given":"Rosalie","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Weil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Will","family":"Nutland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1008-7413","authenticated-orcid":false,"given":"Ismael","family":"Maatouk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7640-9166","authenticated-orcid":false,"given":"Teodora","family":"Wi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6168-6745","authenticated-orcid":false,"given":"Chloe M.","family":"Orkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7227-2545","authenticated-orcid":false,"given":"Rosamund","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"issue":"7","key":"3840_CR1","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/jama.2022.12513","volume":"328","author":"JB Nuzzo","year":"2022","unstructured":"Nuzzo JB, Borio LL, Gostin LO. The WHO Declaration of Monkeypox as a Global Public Health Emergency. JAMA. 2022;328(7):615\u20137.","journal-title":"JAMA"},{"key":"3840_CR2","unstructured":"World Health Organization. 2022\u201323 Mpox (Monkeypox) Outbreak: Global Trends. Available from: https:\/\/worldhealthorg.shinyapps.io\/mpx_global\/"},{"issue":"10370","key":"3840_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0140-6736(22)02075-X","volume":"401","author":"O Mitj\u00e0","year":"2023","unstructured":"Mitj\u00e0 O, Ogoina D, Titanji BK, Galvan C, Muyembe JJ, Marks M, et al. Monkeypox. The Lancet. 2023;401(10370):60\u201374.","journal-title":"The Lancet"},{"issue":"10380","key":"3840_CR4","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(23)00273-8","volume":"401","author":"O Mitj\u00e0","year":"2023","unstructured":"Mitj\u00e0 O, Alemany A, Marks M, Lezama Mora JI, Rodr\u00edguez-Aldama JC, Torres Silva MS, et al. Mpox in people with advanced HIV infection: a global case series. The Lancet. 2023;401(10380):939\u201349.","journal-title":"The Lancet"},{"issue":"12","key":"3840_CR5","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1177\/10497323241234482","volume":"34","author":"AK Smith","year":"2024","unstructured":"Smith AK, Storer D, Lancaster K, Haire B, Newman CE, Paparini S, MacGibbon J, Cornelisse VJ, Broady TR, Lockwood T, McNulty A, Delpech V, Holt M. Mpox illness narratives: stigmatising care and recovery during and after an emergency outbreak. Qual Health Res. 2024;34(12):1161\u201374.","journal-title":"Qual Health Res"},{"key":"3840_CR6","unstructured":"European Medicines Agency. Opinion on Tecovirimat SIGA published in January 2022. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tecovirimat-siga"},{"key":"3840_CR7","unstructured":"European Medicines Agency. Tecovirimat SIGA: EPAR - Product Information. European Medicines Agency; 2023. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecovirimat-siga-epar-product-information_en.pdf"},{"issue":"7","key":"3840_CR8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1056\/NEJMp2210125","volume":"387","author":"A Sherwat","year":"2022","unstructured":"Sherwat A, Brooks JT, Birnkrant D, Kim P. Tecovirimat and the Treatment of Monkeypox \u2014 Past, Present, and Future Considerations. N Engl J Med. 2022;387(7):579\u201381.","journal-title":"N Engl J Med"},{"key":"3840_CR9","unstructured":"Medicines and Healthcare products Regulatory Agency. Clinical Commissioning Rapid Policy Statement: Tecovirimat as treatment for patients hospitalised due to monkeypox virus infection. 2022. Available from: https:\/\/www.cas.mhra.gov.uk\/ViewandAcknowledgment\/ViewAlert.aspx?AlertID=103213"},{"key":"3840_CR10","unstructured":"Collins S. HIV i-Base. 2024. CROI 2024: Studies using tecovirimat to treat mpox. Available from: https:\/\/i-base.info\/htb\/47336"},{"issue":"12","key":"3840_CR11","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1038\/s41564-022-01269-8","volume":"7","author":"G Frenois-Veyrat","year":"2022","unstructured":"Frenois-Veyrat G, Gallardo F, Gorg\u00e9 O, Marcheteau E, Ferraris O, Baidaliuk A, et al. Tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations. Nat Microbiol. 2022;7(12):1951\u20135.","journal-title":"Nat Microbiol"},{"key":"3840_CR12","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID). A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Monkeypox Virus Disease. clinicaltrials.gov; 2024. Report No.: NCT05534984. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05534984"},{"key":"3840_CR13","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID). A Randomized, Placebo-controlled, Double-blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Adult and Pediatric Patients With Monkeypox Virus Disease. clinicaltrials.gov; 2024. Report No.: NCT05559099. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05559099"},{"key":"3840_CR14","unstructured":"Klein M. Placebo-controlled Randomized Trial of Tecovirimat in Non-hospitalized Patients With Monkeypox: Canadian Feasibility Study (PLATINUM-CAN) [Internet]. clinicaltrials.gov; 2022. Report No.: NCT05534165. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05534165"},{"key":"3840_CR15","unstructured":"Alexandra C. A Phase III, Multi-country, Randomized, Placebo-controlled, Double-blinded Trial to Assess the Efficacy and Safety of Tecovirimat Antiviral Treatment for Patients With Monkeypox Virus Disease. clinicaltrials.gov; 2023. Report No.: NCT05597735. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05597735"},{"key":"3840_CR16","unstructured":"Health Research Authority. PLATINUM trial. Available from: https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/application-summaries\/research-summaries\/platinum-trial\/"},{"issue":"5","key":"3840_CR17","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S1473-3099(22)00806-4","volume":"23","author":"DL Fink","year":"2023","unstructured":"Fink DL, Callaby H, Luintel A, Beynon W, Bond H, Lim EY, et al. Clinical features and management of individuals admitted to hospital with monkeypox and associated complications across the UK: a retrospective cohort study. Lancet Infect Dis. 2023;23(5):589\u201397.","journal-title":"Lancet Infect Dis"},{"key":"3840_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/PPA.S24752","volume":"6","author":"CD Barbosa","year":"2012","unstructured":"Barbosa CD, Balp MM, Kulich K, Germain N, Rofail D. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence. 2012;6:39\u201348.","journal-title":"Patient Prefer Adherence"},{"issue":"11","key":"3840_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224964","volume":"14","author":"JA Watkins","year":"2019","unstructured":"Watkins JA, Ross JDC, Thandi S, Brittain C, Kai J, Griffiths F. Acceptability of and treatment preferences for recurrent bacterial vaginosis\u2014Topical lactic acid gel or oral metronidazole antibiotic: Qualitative findings from the VITA trial. PLoS ONE. 2019;14(11): e0224964.","journal-title":"PLoS ONE"},{"key":"3840_CR20","volume-title":"Qualitative Methods for Health Research","author":"J Green","year":"2018","unstructured":"Green J, Thorogood N. Qualitative Methods for Health Research. 4th ed. London: SAGE Publications; 2018.","edition":"4"},{"key":"3840_CR21","unstructured":"Krueger R, Casey M. Focus Groups: A Practical Guide for Applied Research. Thousand Oaks, CA.: SAGE Publications; 2009."},{"issue":"1","key":"3840_CR22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12913-017-2031-8","volume":"17","author":"M Sekhon","year":"2017","unstructured":"Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res. 2017;17(1):88.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"3840_CR23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1471-2288-13-117","volume":"13","author":"NK Gale","year":"2013","unstructured":"Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol. 2013;13(1):117.","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"3840_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1017\/S0033291720001890","volume":"52","author":"D Freeman","year":"2022","unstructured":"Freeman D, Waite F, Rosebrock L, Petit A, Causier C, East A, et al. Coronavirus conspiracy beliefs, mistrust, and compliance with government guidelines in England. Psychol Med. 2022;52(2):251\u201363.","journal-title":"Psychol Med"},{"issue":"5","key":"3840_CR25","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/hiv.13430","volume":"24","author":"S Paparini","year":"2023","unstructured":"Paparini S, Whitacre R, Smuk M, Thornhill J, Mwendera C, Strachan S, et al. Public understanding and awareness of and response to monkeypox virus outbreak: A cross-sectional survey of the most affected communities in the United Kingdom during the 2022 public health emergency. HIV Med. 2023;24(5):544\u201357.","journal-title":"HIV Med"},{"key":"3840_CR26","doi-asserted-by":"crossref","unstructured":"Witzel TC, Ghobrial A, Palich R, Charles H, Rodger AJ, Sabin C, et al. Experiences of mpox illness and case management among cis and trans gay, bisexual and other men who have sex with men in England: a qualitative study. eClinicalMedicine. 2024;70, 102522.","DOI":"10.1016\/j.eclinm.2024.102522"},{"key":"3840_CR27","unstructured":"Office for National Statistics. Coronavirus and the social impacts on Great Britain. 2021. Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/healthandwellbeing\/bulletins\/coronavirusandthesocialimpactsongreatbritain\/29january2021#strengths-and-limitations"},{"issue":"25","key":"3840_CR28","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1016\/j.vaccine.2022.04.030","volume":"40","author":"B Hussain","year":"2022","unstructured":"Hussain B, Latif A, Timmons S, Nkhoma K, Nellums LB. Overcoming COVID-19 vaccine hesitancy among ethnic minorities: A systematic review of UK studies. Vaccine. 2022;40(25):3413\u201332.","journal-title":"Vaccine"},{"issue":"7","key":"3840_CR29","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1080\/13557858.2021.1936464","volume":"27","author":"C Woodhead","year":"2022","unstructured":"Woodhead C, Onwumere J, Rhead R, Bora-White M, Chui Z, Clifford N, et al. Race, ethnicity and COVID-19 vaccination: a qualitative study of UK healthcare staff. Ethn Health. 2022;27(7):1555\u201374.","journal-title":"Ethn Health"},{"issue":"1","key":"3840_CR30","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1186\/s13063-018-2916-9","volume":"19","author":"P Dellson","year":"2018","unstructured":"Dellson P, Nilsson K, Jernstr\u00f6m H, Carlsson C. Patients\u2019 reasoning regarding the decision to participate in clinical cancer trials: an interview study. Trials. 2018;19(1):528.","journal-title":"Trials"},{"issue":"4","key":"3840_CR31","first-page":"703","volume":"28","author":"KM Schaefer","year":"2001","unstructured":"Schaefer KM, Ladd E, Gergits MA, Gyauch L. Backing and forthing: the process of decision making by women considering participation in a breast cancer prevention trial. Oncol Nurs Forum. 2001;28(4):703\u20139.","journal-title":"Oncol Nurs Forum"},{"issue":"11","key":"3840_CR32","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1054\/bjoc.2000.1142","volume":"82","author":"V Jenkins","year":"2000","unstructured":"Jenkins V, Fallowfield L. Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy. Br J Cancer. 2000;82(11):1783\u20138.","journal-title":"Br J Cancer"},{"issue":"27","key":"3840_CR33","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1016\/j.vaccine.2021.05.013","volume":"39","author":"T Nadarzynski","year":"2021","unstructured":"Nadarzynski T, Frost M, Miller D, Wheldon CW, Wiernik BM, Zou H, et al. Vaccine acceptability, uptake and completion amongst men who have sex with men: A systematic review, meta-analysis and theoretical framework. Vaccine. 2021;39(27):3565\u201381.","journal-title":"Vaccine"},{"issue":"1","key":"3840_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29338","volume":"96","author":"W Zhang","year":"2024","unstructured":"Zhang W, Qi X, Yang L, Meng X, Xu G, Luo S, et al. Mpox patients\u2019 experience from infection to treatment and implications for prevention and control: A multicenter qualitative study in China. J Med Virol. 2024;96(1): e29338.","journal-title":"J Med Virol"},{"issue":"12","key":"3840_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3002249","volume":"21","author":"BT Nguyen","year":"2023","unstructured":"Nguyen BT, Marc A, Su\u00f1er C, Marks M, Ubals M, Hern\u00e1ndez-Rodr\u00edguez \u00c1, et al. Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection. PLOS Biol. 2023;21(12): e3002249.","journal-title":"PLOS Biol"},{"issue":"1","key":"3840_CR36","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1186\/s12889-023-17196-0","volume":"23","author":"T May","year":"2023","unstructured":"May T, Towler L, Smith LE, Horwood J, Denford S, Rubin GJ, et al. Mpox knowledge, behaviours and barriers to public health measures among gay, bisexual and other men who have sex with men in the UK: a qualitative study to inform public health guidance and messaging. BMC Public Health. 2023;23(1):2265.","journal-title":"BMC Public Health"},{"key":"3840_CR37","unstructured":"National Department of Health. Media Briefing Statement By The Minister of Health on the Outbreak of Mpox Diseases in South Africa and Efforts to Curb the Spread. 2024; Pretoria, South Africa. Available from: https:\/\/www.health.gov.za\/wp-content\/uploads\/2024\/06\/Minister-of-Health-Dr-Joe-Phaahla-Speaking-Notes-on-Mpox-Desease-12-June-2024.pdf"},{"key":"3840_CR38","unstructured":"National Department of Health. Media statement: Update on mpox outbreak and response efforts. Pretoria, South Africa: National Department of Health; 2024. Available from: https:\/\/www.health.gov.za\/wp-content\/uploads\/2024\/06\/Update-on-mpox-outbreak-and-response-efforts-25-June-2024.pdf"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03840-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-024-03840-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03840-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T14:19:02Z","timestamp":1737469142000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-024-03840-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3840"],"URL":"https:\/\/doi.org\/10.1186\/s12916-024-03840-y","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"18 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for the study was obtained from the Queen Mary Ethics of Research Committee on 20 December 2023 (QMERC23.045). All participants received a participant information sheet and gave written and verbal informed consent to take part in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}},{"value":"CMO has received honoraria for advisory boards, lectureships and travel sponsorships from Janssen, Gilead Sciences, ViiV Healthcare, MSD and Bavarian Nordic and has received research grants from Janssen, Gilead Sciences, ViiV Healthcare, MSD and AstraZeneca. SP has received research grants from Gilead Sciences and ViiV Healthcare. The remaining authors (RH, BW, WN, IM, TW and RL) declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Competing interests"}}],"article-number":"19"}}